65,437 trials
Disorder of Vitamin B12
Primary: Change in Holo-transcobalamin — 124 pmol/L
Dry Eye Syndrome
Primary: Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90 — 8.32; 6.43 Scores on a Scale
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
Carcinoma, Renal Cell
Primary: Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population — 542; 461 days — p=0.146
Invasive Fungal Infections
Primary: The Pharmacokinetics (Area Under the Curve) of Anidulafungin in Infants and Toddlers Less Than 24 Months of Age With Suspected Serious Infection. — 84 µg*h/mL
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 21380.0; 21370.0 ng*hr/mL
Urinary Bladder, Overactive
Primary: Change From Baseline in Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12 — 8.80; 8.48; -2.48; -3.84 Episodes per 24 hours — p=<0.0001
Dry Eye Syndrome
Primary: Change From Baseline in Subjective Evaluation of Symptom of Dryness (SESoD)Score at Day 90 — 2.7; 2.8; 2.8; -0.7 Scores on a Scale
Dry Eye Syndrome
Primary: Tolerability Questionnaire Mean Scores at 1 Week — 70.1; 70.7; 57.3; 65.1 Scores on a scale
Gastrointestinal Endoscopy · Gastrointestinal Polypectomy
Primary: Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 2 Minutes From Beginning of Maintenance Period — 0; 0; 0; 1 Participants
Aneurysm
Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024
Neoplasms, Prostate · Prostate Cancer After a Radical Treatment
Primary: Time to Prostate-specific Antigen (PSA) Doubling From Baseline (in Days) — 365.5; 458.0; NA; NA days — p=<0.001
Perforated Appendicitis
Primary: Abscess After Appendectomy — 10; 10 number of patients
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF]) — -0.73; -0.32 Percentage of change — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin